SensiVida Medical Systems
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SensiVida Medical Systems
Deal-making between big pharma and biotech looks set to rise with a looming patent cliff increasing the need for the former to replenish its pipelines. Meanwhile, biotechs need partners to help them advance amid the ongoing big freeze on raising cash on public markets.
Private Company Edition: Third quarter venture capital funding for biopharmaceutical firms fell from Q2, but activity remains near all-time highs year-to-date. Several companies announced VC financings in early October, including Ascidian, which launched with $50m in series A financing.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
- Diagnostic Equipment & Supplies
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
In Vitro Diagnostics
- Glucose Testing
- Hematology, Coagulation
- Therapeutic Drug Monitoring
- Other Names / Subsidiaries
- Mediscience Technology Corp.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.